Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge

Pfizer Inc posted third-quarter profit well above analysts' estimates on higher sales of cancer drug Ibrance and new heart medicine Vyndaqel, encouraging the largest U.S. drugmaker to lift its earnings forecast for the year.